Navigation Links
Injectable Drug Delivery to 2016

NEW YORK, Sept. 13, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Injectable Drug Delivery to 2016

The past decade has seen a dramatic shift in terms of the types of approved injectable drugs, the diseases they target, and the devices used to deliver them. This shift has fostered change on several levels of the healthcare sector. The injectable drug segment has seen a marked increase in the level of drug/device integration, as prefilled syringes and specialized injection devices proliferate in response to safety and economic challenges posed by recombinant protein drugs, while administration of injectables has moved increasingly from practitioner offices and healthcare facilities to patient homes. This report examines the key therapeutic, product, market and regulatory factors for injectable drugs across ten major disease and therapeutic classes, providing essential insight and forecasts into the implications of this evolving landscape.


  • Analyzes and evaluates the shifting landscape for injectable drug delivery and assesses the market impact of new and emerging injectable drug products by therapeutic indication
  • Analyzes syringe and injector device designs, feature/functionality, product branding, competing technologies and market development issues
  • Provides detailed descriptions of key injectable drug therapeutic market segments, market demographics, and business strategies
  • Forecasts Injectable drug product demand by indication and therapy to 2016• Profiles leading injection device companies, their product development activities, business strategies, and corporate alliances and affiliations Executive Summary

Injectable Drug Delivery Market Dynamics

The Injectable Drug Ecosystem Injectable Drug Demand Drivers Drug Development Factors Market Factors Technology Factors Competitive Landscape Autoinjectors Needle-free Injectors Pen Injectors Prefilled Syringes Safety Syringes Injectable Drug Demand Drivers Diseases and Indications Patient Demographics Developing Economies Risks and Opportunities

Injectable Drug Device Selection Criteria

Stability and Material Selection Issues Single vs Multi-Dose Devices Lyophilized Drugs/Reconstitution Syringe Safety/Sharps Protection Needle Configuration Strategies Disposable Drug Cartridges Human Engineering/Ergonomics Branding/Private Labeling

Injectable Drug Delivery – Device Segments

Autoinjectors Autoinjector-specific Selection Factors Part Counts and Device Cost Safety Features Needle Shielding Needle Insertion Depth Failsafe Activation Dose Inspection/Injection Confirmation Autoinjector Device Categories Reusable Autoinjectors Disposable Autoinjectors Product Specific Autoinjectors Drugs and Therapeutic Segments

Needle-free Injectors

Device Categories

End User/Practitioner/Mass Immunization Injectors

Prefilled Disposable Models

Refillable Cartridge Designs

Needle-free Injector-specific Selection Factors

Energy Source

Injection Site Selection

Pen Injectors Pen Injector Device Categories Standardized Pen Platforms Custom Pen Designs Reusable Pens Prefilled Pen Cartridges Disposable Pens Dual Chamber Pens Branded Drug/Pen Injector Product by Therapeutic Segment

Prefilled Syringes

Prefilled Syringe Device Categories

Glass Prefilled Syringes

Prefillable Glass Syringe Manufacturers and Branded Devices

Branded Drug/Prefilled Glass Syringe Products by Therapeutic Segment

Plastic Prefilled Syringes

Branded Prefillable Plastic Syringes

Drugs and Therapeutic Segments

Prefillable Safety Syringes

Prefilled Syringe-specific Selection Factors

PFS Manufacturing Factors

Fill-and-Finish Operations

Safety Syringes Safety Syringe Device Categories Prefillable Integrated Safety Syringes Non-Prefillable Integrated Safety Syringes Retractable Needle Manually Retractable Automatic Retractable Sliding Sheath

Injectable Drug Delivery – Therapeutic Segment Analysis & Forecasts

Anaphylaxis Anticoagulants Antivirals Autoimmune Diseases Emergency Medicine Hematopoietics Hormone Replacement Metabolic Diseases Neurology Reproductive Health Vaccines

Injectable Drug Therapeutics - Market Factors

Regulatory Factors and Issues FDA Regulations Regulating Combination Products Sharps Legislations Growth and Diversity of Safety Syringes Sharps Disposal Clinical Trial Factors Managed Care and Healthcare Economics

Company Profiles

To order this report: Drug_Delivery_Technology Industry: Injectable Drug Delivery to 2016

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Summer Is the Best Time for Injectable Treatments
2. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
3. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
4. Philips continues to improve access to treatment for common cause of death in the U.S. with the delivery of its one-millionth AED
5. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
6. GeNO LLC Receives Four Additional Patents for Inhaled Nitric Oxide Delivery
7. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
8. GeNO LLC Receives FDA Marketing Clearance For Its Inhaled Nitric Oxide Drug Delivery Device
9. AHM Announces New SVP Product Delivery
10. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
11. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
Post Your Comments:
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):